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OBJECTIVES: To report on a simple practical test for assessing acute estradiol vascular effects on healthy and unhealthy
postmenopausal women.
INTRODUCTION: Estradiol acts in the endothelium to promote vasodilatation through genomic and non-genomic mechanisms,
but its vascular action may be impaired in diabetes mellitus, hypertension, smoking and obesity.
METHODS: Nineteen postmenopausal women (nine healthy and 10 with two or more of the above factors) of similar age and time
since menopause were examined with vascular Doppler ultrasound. Resistance indexes and systolic and diastolic flow velocities
were determined for the brachial and internal carotid arteries at baseline and 20 minutes after administration of a nasal estradiol
formulation, available on the market, which reaches 1,200-1,500 pg/ml in the serum in 10-30 minutes. Estradiol blood levels were
measured at 30 minutes.
RESULTS: The carotid resistance index increased 14.2% (vasoconstriction) in the unhealthy group after estradiol, from a mean ±
S.E. of 0.56 ± 0.016 at baseline to 0.64 ± 0.05 (p=0.033), and remained unchanged in healthy women. Brachial diastolic flow
velocity increased 19.7% (vasodilatation) in healthy women, from 16.2 ± 1.93 to 19.4 ± 0.64 cm/s (p=0.046), and did not change in
the unhealthy subjects. Estradiol levels were similar in both groups.
DISCUSSION: Healthy postmenopausal women showed brachial vasodilatation while unhealthy postmenopausal women displayed
vasoconstriction at the carotid artery. Vascular responses to estradiol were divergent between the groups.
CONCLUSIONS: The acute estradiol test, coupled with Doppler ultrasound, seemed to be able to differentiate women with
normal and abnormal endothelial function in a simple, non-invasive manner.
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INTRODUCTION
The cardiovascular benefits of estrogen during meno-
pause are currently controversial. Observational studies
have shown a reduction of 40 to 50% in coronary disease
risk in women continuously using hormonal replacement
therapy from the onset of menopause (8.5 to 20 years1,2).
On the other hand, in the prospective randomized, double-
blind Women’s Health Initiative (WHI) study, women who
received estrogen + progesterone therapy3 had an increased
risk of cardiovascular events after 5.2 years of treatment
(RR 1.29). In women using only estrogen therapy (ET), the
reduction of cardiovascular risk was not significant (RR
0.91) after seven years.4 It should be noted, however, that
the WHI study recruited women with a mean age of 63
years; that is, 13 years after the onset of menopause and
with a great prevalence of associated pathologies, such as
arterial hypertension, diabetes mellitus and obesity. The
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possible existence of a “window of opportunity” for
estrogen for cardiovascular protection during menopause
has been suggested.5 In 1996, Clarkson6 demonstrated that
estrogen was able to promote primary prevention of arte-
riosclerosis in female monkeys when administered imme-
diately after oophorectomy. Later, the same author observed
a total loss of this benefit if ET was postponed for the
equivalent of six years in women.7
The window of opportunity could be connected to vascu-
lar endothelium integrity, the main site of estradiol’s
cardioprotection mechanisms.8 Estradiol’s influences on the
endothelium are complex.9 The vasomotor effect depends
upon a genomic action on β-estrogen receptors, which acti-
vate nitric oxide (NO) synthase and consequently increase
NO production, thus modulating vasoreactivity. Increased NO
production elicits vasodilatation in arteries with a normal
endothelium and might attenuate or even abolish it in arter-
ies with endothelial dysfunction.10,11 Estradiol also acts on
endothelium and vascular smooth muscle cell calcium chan-
nels, promoting a short-lasting vasodilatation immediately
after its administration. Estradiol treatment inhibits voltage-
dependent type 2 Ca++ channels and controls K+ flow through
the membrane, opening voltage-activated cAMP-dependent
K+ and Ca++ channels. This action has recently been dem-
onstrated, and is mediated by α-estrogen receptors present
in smooth muscle cells of the coronary vascular wall.12
Several risk factors implicated in the pathophysiology of
cardiovascular diseases, such as smoking, arterial hyperten-
sion, dyslipidemia and diabetes mellitus, have endothelial
dysfunction as a common denominator13-15 with predominant
vasoconstrictor activity and a reduction of NO biological ac-
tivity, implicating increased vascular vulnerability.
The question we have tried to answer is this: how can
one evaluate in a simple and practical way if the endothe-
lium is healthy and can respond to estrogen, with poten-
tial cardiovascular benefit, in postmenopausal women? To
answer this question, we developed a test to evaluate vas-
cular reactivity using vascular Doppler ultrasound and ex-
plored the acute effects of a new 17β-estradiol formulation
for nasal administration. Ten to 30 minutes after its appli-
cation, serum levels of estradiol reach a peak of 1,200 to
1,500 pg/dl, values much greater than the maximum val-
ues found during menacme (400 pg/dl). Such high levels
rapidly fall, but with estrogen receptor saturation, the ge-
nomic effect persists for 24 hours and is comparable to
other forms of hormonal replacement.16
Here we describe a pilot study of this test. The objec-
tives of the present work were to verify if acute vascular
response to high levels of estradiol were different in healthy
versus unhealthy women and if the test could be useful for
vascular evaluation during menopause.
MATERIALS AND METHODS
Nineteen women from the Menopause Clinic currently
using hormone therapy for climacteric syndrome were se-
lected based on their records and according to the follow-
ing criteria: spontaneous (at least one year of amenorrhea)
or surgical (hysterectomy with bilateral oophorectomy)
menopause; age less than 60 years; healthy (group I), with-
out any known cardiovascular risk factor (n=9), or un-
healthy (group II), with two or more risk factors, such as
hypertension, diabetes mellitus, obesity and smoking, but
without any previous cardiovascular event, such as myo-
cardial infarction, angina pectoris or stroke (n=10).
Arterial hypertension was defined by two separate meas-
ures of blood pressure higher than 140/90 mmHg or by a
previous diagnosis when the woman was using anti-hyper-
tensive therapy. Diabetes mellitus was confirmed by two
separate determinations of fasting glucose higher than 126
mg/dl or by a previous diagnosis when the patient was us-
ing an oral hypoglycemic agent. Obesity was defined when
the body mass index (BMI, mass in kg divided by the
squared height in meters) was higher than 30.
Exclusion criteria were hypertension not well control-
led by medication (>160/100 mmHg), hyper- or hypothy-
roidism and use of medication that could interfere in the
test with acute estradiol, such as calcium channel blockers,
sulfonylureas, corticoids and drugs with actions on the cen-
tral nervous system.
Patients that agreed to participate in the study had an
appointment made in the afternoon at the ultrasound clinic.
They were told not to use hormonal replacement therapy,
any medication with action on the central nervous system
or alcohol 40 hours prior to the Doppler exam. It was also
asked that they did not eat, consume drinks that contained
caffeine (coffee, black tea or soda with coca) or smoke for
two hours before the exam.
In the clinic, before the procedure, every step of the
study was explained to participants and they signed a writ-
ten informed consent, per the protocol approved by the In-
stitutional Review Board.
The blood pressures of the participants were measured
with a Tycos apparatus within 5 min of their arrival and three
times during a period of 30 min, with the lowest value re-
corded considered to be the baseline value. During these
measurements, the participants were kept in the waiting
room, seated, in a relative restful and calm environment. Af-
ter at least 30 min, basal vascular ultrasound (ATL HDI 3000,
coupled with a probe of 7.5 MHz) was performed. The fol-
lowing parameters were analyzed in the brachial and inter-
nal carotid arteries at an identical angle (not greater than
60º): resistance index (RI, to infer changes in vascular di-
675
CLINICS 2007;62(6):673-8 Use of vascular doppler ultrasound to detect acute estradiol vascular effect in postmenopausal women
Clapauch R et al.
ameter) and systolic (SF) and diastolic (DF) flow velocities.
After these measurements, the patients returned to the wait-
ing room and received 150 µg of 17β-estradiol through a na-
sal spray in each nostril (total of 300 µg) and had their blood
pressure measured 10, 20 and 30 min afterward. A second vas-
cular ultrasound was made within 20 min after nasal admin-
istration of 17β-estradiol and the same parameters of the first
exam were evaluated. Vasodilatation was inferred from a de-
crease in RI and/or an increase in DF, and vasoconstriction
was inferred from the opposite results (an increased RI and/
or a decreased DF). After the last blood pressure measurement,
blood was collected to quantify serum levels and prove the ab-
sorption of 17β-estradiol by the nasal route.
Statistical analysis
To evaluate if the groups could be compared, means and
proportions were made using the paired t-test or χ2, as ap-
plicable. Fischer’s exact test was used when there were re-
strictions on the use of χ2. The effects of nasal estradiol
on blood pressure and on Doppler vascular responses were
analyzed using the GLM procedure for repeated measure-
ments, according to the SPSS package, version 12, which
allows for comparison of more than two series (e.g., con-
trol time, 10, 20 and 30 min) with the influence of other
variables, such as age and menopausal time. Results were
considered significantly different for p<0.05.
RESULTS
No significant difference could be found between healthy
and unhealthy women for age (control mean ± S.D. 50.6 ±
8.5 and unhealthy group 52.0 ± 4.8 years, p=0.65), age
when menopause occurred (44.1 ± 7.8 versus 44.5 ± 6.2
years, respectively, p=0.91) or time elapsed since menopause
(6.4 ± 3.5 versus 7.5 ± 5.0 years, respectively, p=0.61). For
each group, five women were hysterectomized and
oophorectomized and used only transdermal estrogen; the
others used transdermal estrogen associated with cyclical
dihydrogesterone.
Among unhealthy women, the most prevalent morbid-
ity was hypertension (10/10), followed by diabetes mellitus
(7/10), obesity (3/10) and smoking (3/10). In this group,
three women had three risk factors for cardiovascular dis-
ease, and the others had two.
The mean BMI ± S.D. for the healthy group was 26.2-
±3.0 kg/m2, which is characteristic of being overweight, but
none were obese (BMI>30). On the other hand, in the un-
healthy group, there were three obese patients, but the mean
BMI was not statistically different from that observed for
the healthy group (29.8 ± 4.9 kg/m2, p=0.078).
No significant change in blood pressure could be de-
tected during the whole procedure. Mean estradiol levels
30 min after nasal administration were similar for both
groups: 581 ± 378 (healthy group) and 575 ± 194 pg/ml
(unhealthy group, p=0.967).
The Doppler ultrasound measurements at baseline were
not different between the groups, but the carotid resistance
index and brachial diastolic flow velocity responses to
estradiol were divergent. For healthy women, there was no
change in the carotid RI, from a mean ± S.E of 0.60 ± 0.023
at baseline to 0.56 ± 0.02 after estradiol (p=0.48). How-
ever, for the unhealthy group, the carotid RI increased
14.2% after estradiol, from 0.56 ± 0.016 at baseline to 0.64
± 0.05 (p=0.033). Carotid RI variation after estradiol is
shown in Figure 1. There was an opposite response between
healthy and unhealthy women (p=0.028).
Diastolic flow velocity increased 19.7% at the brachial
artery in the healthy group after estradiol treatment (from a
mean ± S.E of 16.2 ±1.93 to 19.4 ± 0.64 cm/s, p=0.046).
For the unhealthy group, brachial DF did not change (17.7
± 1.63 to 16.7 ± 1.83, p=0.314). Brachial DF variation after
estradiol is represented in Figure 2. The response was almost
significantly different between the two groups (p=0.055).
No differences in systolic flow velocity, brachial RI or
carotid DF could be detected in the two groups after
estradiol. At the carotid artery, the SF of healthy women
changed from a mean ± S.E of 52.2 ± 2.7 to 54.0 ± 2.1
cm/s. The carotid SF in unhealthy women varied from 58.9
± 4.7 to 58.9 ± 4.6 cm/s (p=0.820 for the response to
estradiol for both groups and p=0.682 for the response in
* Unhealthy group baseline vs. after estradiol: p=0.033.
** Response to estradiol healthy vs. unhealthy women: p=0.028.
Figure 1 - Carotid resistance index before and 20 min after nasal administration
of 300 µg of 17β-estradiol in healthy and unhealthy women.
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each group, healthy and non-healthy). At the brachial ar-
tery, the SF of healthy women changed from 66.5 ± 5.35
to 73.5 ± 6.1 cm/s and the SF of unhealthy women changed
from 62.2 ± 4.7 to 58.4 ± 6.4 cm/s after estradiol (p=0.06
for response to estradiol for both groups and 0.084 for re-
sponse in each group).
DISCUSSION
After acute administration of 17β-estradiol, healthy
postmenopausal women showed increased brachial artery
DF (vasodilatation) and unhealthy ones showed increased
carotid artery resistance (vasoconstriction).
The mechanisms of estrogen vascular action include NO
production and Ca++ channel blockade. The final effect de-
pends on the endothelium integrity and elasticity (degree of
stiffness) of the arterial wall. Our results suggest that healthy
postmenopausal women, i.e., without risk factors for cardio-
vascular disease, showed the vasodilator effect at the brachial
artery expected after nasal administration of 17β-estradiol,
which possibly correlates with better vascular function at the
endothelial layer and better elasticity of the vascular wall.
Several other studies have confirmed beneficial effects
from estrogen by different administration pathways (oral,
transdermic or intranasal) on vascular resistance in healthy
women.17-19 Zegura and co-workers17 reported that oral or
transdermal estradiol replacement for a period of 28 weeks
improved the endothelial function of middle-aged healthy
women six weeks after surgical menopause. In this study,
endothelium-dependent and –independent dilatation was
evaluated by measuring the brachial artery diameter with
high resolution Doppler ultrasound at rest, after reactive
hyperemia and following administration of sublingual ni-
trate. Endothelium-dependent vasodilatation increased af-
ter oral (from 6.0 ± 3.9% to 13.2 ± 4.4%, p<0.001) and
transdermal (from 7.0 ± 4.9% to 14.9 ± 5.7%, p<0.001)
estradiol administration. Endothelium-independent va-
sodilatation did not change.
Acar and co-workers,18 in an experimental, randomized,
placebo-controlled, double-blinded cross-over study, evalu-
ated the acute effect of nasal 17β-estradiol on cerebral
blood flow, as measured by Doppler ultrasound, on 18
healthy 42-58 year old women after natural menopause oc-
curring 3.6 ± 2.6 years previously. There was a significant
increase in internal carotid and vertebral artery and cerebral
blood flow compared with placebo. The study concluded
that this effect could protect against cerebral atrophy and
dementia and improve cognitive function.
Lima19 investigated the effect of an acute, sublingual,
therapeutic/low dose of 17β-estradiol on seven postmeno-
pausal women with mild hypertension (diastolic pressure 90-
110 mmHg and systolic pressure 140-180 mmHg) and no
other cardiovascular risk factors. Diabetes mellitus,
dyslipidemia and smoking were exclusion criteria and mean
BMI was 25 kg/m2. Eight normotensive women of similar
ages and BMI served as controls. Forearm blood flow (FBF)
was measured during intrabrachial infusion of increasing
doses of acetylcholine and sodium nitroprusside, before and
after 1 mg of sublingual 17β-estradiol. Before estradiol ap-
plication, FBF was similar for both groups. After adminis-
tration, FBF significantly improved for increasing doses of
acetylcholine in both groups (normotensives, maximal re-
sponse: 17.6 ± 5.0 versus 22.5 ± 7.0 ml/min/100 ml and
hypertensives: 11.0 ± 4.0 versus 16.0 ± 6; 12.0 ± 4.0 versus
17.0 ± 5.0 and 14.0 ± 3.0 versus 20.0 ± 7.0 ml/min/100 ml).
Acute administration of 17β-estradiol did not change the
dose-response curve for sodium nitroprusside in either group.
The authors concluded that these women, with mild arterial
hypertension but without other cardiovascular risk factors,
still had an estrogen-responsive endothelium.
In our study, the carotid RI response to acute adminis-
tration of 17β-estradiol was different in healthy and un-
healthy postmenopausal women. Unhealthy women showed
significant vasoconstriction of the carotid artery after 17β-
estradiol treatment, suggesting that their arteries were al-
ready damaged, either at the endothelial layer or at the vas-
cular wall itself (reduction of elasticity). We selected a dis-
tinct group of women, with at least two cardiovascular risk
factors impairing endothelial function, in order to better
demonstrate if there was a different vascular response to
acutely high levels of estradiol compared to controls. Fac-
* Healthy group baseline vs. after estradiol: p=0.046.
Figure 2 - Brachial diastolic blood flow velocity (cm/s) before and 20 min
after nasal administration of 300 µg of 17β-estradiol in healthy and unhealth
women.
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tors such as hypertension, diabetes mellitus, smoking and
obesity can damage endothelial cells, leading to endothe-
lial dysfunction, impaired NO production and increased re-
active oxygen species (ROS) production, with clinical con-
sequences such as vasospasm, thrombosis and/or arterioscle-
rosis. The latter deteriorates arterial wall elasticity through
accumulation of smooth muscle cells and Ca++, contribut-
ing to increased arterial wall stiffness. Increased stiffness
and parietal thickness, present in advanced arteriosclero-
sis, could limit maximum vasodilatation of an artery.
White and co-workers,20 in an experimental study with
porcine endothelium-denuded coronary arteries, performed
isometric contractile force recordings and identified signaling
molecules in coronary smooth muscle cells while estrogen
was added. Estrogen relaxed arteries through endothelium-
independent mechanisms at the smooth muscle level. When
arteries were pretreated with agents that impaired NO pro-
duction, estrogen promoted contraction instead of dilatation.
Reduction of superoxide (O2–) radicals attenuated this con-
traction. The authors proposed a dual mechanism by which
estrogen could act on the type 1 neuronal NOS isoform
(nNOS), present in myocytes, leading to vasodilatation by
NO production or vasoconstriction by O2– release.
It is possible to question if the increase in the carotid
resistance index could be deleterious to this group of pa-
tients. During the study, women did not report adverse re-
actions and high levels of estradiol were transitory. Stud-
ies such as WHI3,4 and HERS,21 which analyzed hormonal
replacement effects on women with mean ages of 63 and
67 years, respectively, and the latter with coronary artery
disease, showed a significant increase in the relative risk
of stroke. Existing vascular damage when estrogen replace-
ment therapy is initiated could facilitate carotid vasocon-
striction and decrease cerebral blood flow.
The carotid resistance index and brachial diastolic flow
velocity were the ultrasound parameters where the differences
between healthy and unhealthy women could best be observed
in our test. The acute response to nasal 17β-estradiol detected
by Doppler ultrasound could differentiate, in a simple, non-
invasive manner, healthy and unhealthy post-menopausal
women. Currently, the gold standard to evaluate endothelial
function is venous occlusion plethysmography,22 where arm
blood flow is measured during infusions of increasing doses
of acetylcholine into the brachial artery. This classical tech-
nique requires an intra-arterial injection of a vasodilatory sub-
stance. This exam is neither available nor specific for 17β-
estradiol action.
CONCLUSIONS
Although this is a preliminary study with a small
number of women, the acute response to nasal 17β-estradiol
measured with Doppler ultrasound seemed able to differ-
entiate women with normal and abnormal endothelial func-
tion in a simple, non-invasive manner.
The resistance index of the carotid artery and the
diastolic flow velocity of brachial artery were the ultrasound
parameters that best showed this difference: healthy women
showed brachial vasodilatation, while unhealthy women
displayed vasoconstriction at the carotid level. Vascular re-
sponses to estradiol were divergent between the groups.
The present test described here could be a practical al-
ternative to evaluate potential vascular estrogen benefits and
risks in postmenopausal women. We intend to perform ad-
ditional studies with a larger number of women with spe-
cific pathologies to further identify estrogen vascular ac-
tion according to endothelial status.
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RESUMO
avaliar o efeito vascular agudo do estradiol em mulheres
saudáveis e não-saudáveis na menopausa.
INTRODUÇÃO: O estradiol atua no endotélio promovendo
vasodilatação através de mecanismos genômicos e não-
genômicos e esta ação pode estar prejudicada em morbidades
como diabetes mellitus, hipertensão, tabagismo e obesidade.
Clapauch R, Mattos TM, Uchoa HBMP, Ferreira ASR,
Bonisson VG, Lopes EL, Nascimento ICS, Bouskela E. Uso
do Doppler vascular para detectar o efeito agudo do estradiol
em mulheres na pós-menopausa. Clinics. 2007;62(6):673-8.
OBJETIVO: Descrever um teste simples e prático para
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MÉTODOS: Dezenove mulheres na pós-menopausa (9
saudáveis e 10 com dois ou mais dos fatores acima), com
idade e tempo de menopausa semelhantes foram exami-
nadas por Doppler vascular. O índice de resistência e as
velocidades de fluxo sistólico e diastólico foram medidos
nas artérias braquial e carótida, em condições basais e 20
min após a administração de uma preparação nasal de
estradiol, disponível comercialmente, que atinge 1200 a
1500 pg/ml no soro, entre 10 e 30 min após a aplicação.
Os níveis séricos de estradiol foram determinados 30 min
após a aplicação nasal.
RESULTADOS: O índice de resistência da artéria carótida
aumentou em 14,2% (vasoconstricção) após o estradiol no
grupo não-saudável, partindo da média ± SE de 0,56 ± 0,016
para 0,64 ± 0,05 (p=0,033) e não se modificou nas mulheres
saudáveis. A velocidade de fluxo diastólico da artéria
braquial aumentou 19,7% (vasodilatação) nas mulheres
saudáveis, partindo de 16,2 ± 1,93 para 19,4 ± 0,64 cm/s
(p=0,046) e não apresentou alteração nas não saudáveis. Os
níveis de estradiol foram semelhantes nos dois grupos.
DISCUSSÃO: Nas mulheres saudáveis na menopausa
houve vasodilatação da artéria braquial e nas não-saudáveis
vasoconstricção na artéria carótida. A resposta vascular ao
estradiol foi divergente entre os grupos estudados.
CONCLUSÃO: O teste com estradiol agudo, associado ao
Doppler vascular, parecem diferenciar, de forma simples e não-
invasiva, mulheres com função endotelial normal e anormal.
UNITERMOS: Terapia de reposição hormonal. Estrogênio.
Endotélio vascular. Vasodilatação. Vasoconstricção.
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